Explore OX40/OX40L inhibition in atopic dermatitis: phase 3 amlitelimab efficacy, safety signals, and what upstream immune control could mean.
ABCs in Dermatology
Late-breaking AAD 2026 trials spotlight PsA weight-loss combo, twice-yearly IL-13 dosing for atopic dermatitis, and a rapid oral TYK2 pill for psoriasis.
Chris Bunick, MD, PhD, and Lindsay Ackerman, MD, preview the 2026 American Academy of Dermatology Annual Meeting.
Experts unpack biologics, molecular know-how, and patient trust—plus key previews for the upcoming AAD Annual Meeting.
Advertisement
Advertisement
Trending on HCPLive
1
Diagnostic Pearls and New Therapies in Connective Tissue Disease, With Michelle Min, MD
2
Rethinking “Type 2”: Inside the 2026 AACE Diabetes Classification Algorithm
3
VIASKIN Peanut Patch Efficacy Holds in Kids With Atopic Comorbidities
4
Fezolinetant Shows No CNS Safety Signal in Pooled Analysis of 3100 Women, With Marla Shapiro, CM
5